AIDS researchers isolate new potent and broadly effective antibodies against HIV

Discovery provides new directions for AIDS vaccine design

2011-08-19

(Press-News.org) NEW YORK, NY, LA JOLLA and SOUTH SAN FRANCISCO, CA, SEATTLE, WA, August 17, 2011 — A team of researchers at and associated with the International AIDS Vaccine Initiative (IAVI), The Scripps Research Institute, the biotechnology company Theraclone Sciences and Monogram Biosciences Inc., a LabCorp company, report in the current issue of Nature the isolation of 17 novel antibodies capable of neutralizing a broad spectrum of variants of HIV, the virus that causes AIDS.

The new antibodies, large protein molecules that bind to pathogens and flag them for destruction, were isolated from blood serum samples collected in a continuing global search for broadly neutralizing antibodies (bNAbs) launched by IAVI. They should provide researchers with a new set of targets for the design of vaccine candidates that can elicit similar antibodies to protect people from contracting HIV. Some of the bNAbs blocked HIV infection of cells as much as 10 to 100 times as potently as previously discovered bNAbs.

"Most antiviral vaccines depend on stimulating the antibody response to work effectively," said Dennis Burton, a professor of immunology and microbial science and director of the IAVI Neutralizing Antibody Center at The Scripps Research Institute in La Jolla, Calif. Professor Burton, one of the senior authors of the study, is also a member of the Ragon Institute, in Cambridge, Mass. "Because of HIV's remarkable variability, an effective HIV vaccine will probably have to elicit broadly neutralizing antibodies. This is why we expect that these new antibodies will prove to be valuable assets to the field of AIDS vaccine research." Only a minority of people who are HIV-positive begin to produce bNAbs after several years of infection. Animal studies suggest that such antibodies could block HIV infection if they were elicited by a preventive vaccine. Researchers prize bNAbs because their structural and biochemical analysis can reveal how to achieve a preventive vaccine. Specifically, scientists expect that they can use information about how bNAbs bind to HIV to construct immunogens—the active ingredients of vaccines—that elicit similar antibodies. The potency of bNAbs matter because a highly potent antibody could confer such protection at relatively low levels.

"Solving the neutralizing antibody problem is perhaps the greatest challenge facing the field today," said IAVI's chief scientific officer, Wayne Koff. "IAVI concluded many years ago that unlocking the information stored in bNAbs was going to be essential to the fulfillment of our mission—ensuring the design and development of broadly effective AIDS vaccines. This is why we support several laboratories around the world that are designing novel vaccine candidates on the basis of what we're learning from such antibodies. We have no doubt that these new bNAbs will contribute a great deal to our own immunogen design efforts and, we hope, those of other researchers working on AIDS vaccines."

In that regard, the new bNAbs are encouraging. Many of them bind hitherto unknown molecular structures, or epitopes, on the surface of HIV. This means that they could significantly broaden the target options researchers have in designing vaccines to elicit similar antibodies.

How the antibodies were discovered

The 17 new bNAbs described in the current Nature report were isolated from four HIV-positive individuals. The effort, sponsored by IAVI, is unprecedented in scale and distinguished by its emphasis on identifying antibodies that neutralize subtypes of HIV circulating primarily in developing countries. It had previously yielded three potent bNAbs, two of which, PG9 and PG16, were isolated by this research team in 2009 and described in the journal Science. Another bNAb was subsequently isolated from these samples by researchers at the Vaccine Research Center of the National Institutes of Health, who have also discovered a set of bNAbs from separate blood samples using an entirely different approach.

Both the previous and current studies used Theraclone Science's highly sensitive I-STAR™ technology to isolate the antibodies. The new crop of bNAbs, like PG9 and PG16, was rescued from cell cultures derived from single antibody-producing B cells used for antibody discovery and development. Theraclone Sciences Executive Chair and Interim CEO, Steven Gillis commented, "We're delighted that I-STAR has provided essential support in identifying bNAbs that will contribute to advancing AIDS vaccine development. In this project, and in our own infectious disease and cancer programs, the I-STAR platform continues to demonstrate a remarkably powerful ability to isolate rare antibodies with unique properties. Theraclone values these collaborative opportunities in which I-STAR can be used to help improve treatment for critical diseases."

Monogram Biosciences, which also participated in the discovery of PG9 and PG16, conducted the neutralization assays essential to isolating the new bNAbs. The serum samples from which they were isolated represent the top 1% of all such samples gathered by IAVI and its partners, in terms of the number of HIV variants they neutralize and the potency with which they do so.

"Monogram has developed a highly skilled scientific team capable of taking on a variety of biomedical challenges," said Chris Petropoulos, Vice President, Laboratory Corporation of America Holdings, Research and Development, Monogram Biosciences. "Their expertise and innovation has been invaluable to the discovery of these new antibodies. This research illustrates the important role different sectors of the research and health care community can play in supporting global health initiatives."

The analysis of the new antibodies also hints at how future vaccines ought to be formulated to maximize their effectiveness. On the basis of their analyses, the authors of the report conclude that AIDS vaccine candidates that seek to effectively harness the antibody response should probably attempt to elicit certain combinations of bNAbs if they are to provide truly comprehensive protection from HIV.

### The published study on the 17 new bNAbs is available online at www.nature.com

ABOUT IAVI The International AIDS Vaccine Initiative (IAVI) is a global not-for-profit organization whose mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world. Founded in 1996, IAVI works with partners in 25 countries to research, design and develop AIDS vaccine candidates. In addition, IAVI conducts policy analyses and serves as an advocate for the AIDS vaccine field. IAVI supports a comprehensive approach to addressing HIV and AIDS that balances the expansion and strengthening of existing HIV-prevention and treatment programs with targeted investments in the design and development of new tools to prevent HIV. IAVI is dedicated to ensuring that a future AIDS vaccine will be available and accessible to all who need it. IAVI relies on the generous donations from governments, private individuals, corporations and foundations to carry out its mission. For more information, see www.iavi.org.

ABOUT THE SCRIPPS RESEARCH INSTITUTE The Scripps Research Institute is one of the world's largest independent, non-profit biomedical research organizations. Scripps Research is internationally recognized for its discoveries in immunology, molecular and cellular biology, chemistry, neuroscience, and vaccine development, as well as for its insights into autoimmune, cardiovascular, and infectious disease. Headquartered in La Jolla, California, the institute also includes a campus in Jupiter, Florida, where scientists focus on drug discovery and technology development in addition to basic biomedical science. Scripps Research currently employs about 3,000 scientists, staff, postdoctoral fellows, and graduate students on its two campuses. The institute's graduate program, which awards Ph.D. degrees in biology and chemistry, is ranked among the top ten such programs in the nation. For more information, see www.scripps.edu

ABOUT THERACLONE SCIENCES Theraclone Sciences is a Seattle‐based, discovery‐stage biotechnology company focused on the development of novel therapeutic antibodies for the treatment of infectious disease, inflammation and cancer. The company's technology harnesses the power of the human immune system to identify rare, naturally evolved antibodies from the blood cells of immunologically relevant human subjects. Human monoclonal antibodies can be rapidly isolated using the I‐STAR™ discovery platform and scaled for industrial production. Such human antibody drug candidates may be uniquely safe and relevant to combating disease across broad patient populations. Theraclone is a privately held company with venture investment from ARCH Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital, and Alexandria Real Estate Investment. For additional information, please visit www.theraclone-sciences.com.

ABOUT LABORATORY CORPORATION OF AMERICA Laboratory Corporation of America® Holdings, an S&P 500 company, is a pioneer in commercializing new diagnostic technologies and the first in its industry to embrace genomic testing. With annual revenues of $5.0 billion in 2010, over 31,000 employees worldwide, and more than 220,000 clients, LabCorp offers a broad test menu ranging from routine blood analyses to reproductive genetics to DNA sequencing. LabCorp furthers its scientific expertise and innovative clinical testing technology with its Centers of Excellence: The Center for Molecular Biology and Pathology, National Genetics Institute, ViroMed Laboratories, Inc., The Center for Esoteric Testing, Litholink Corporation, Genzyme GeneticsSM*, DIANON Systems, Inc., US LABS, Monogram Biosciences, Inc., and Esoterix and its Colorado Coagulation, Endocrine Sciences, and Cytometry Associates laboratories. LabCorp conducts clinical trials testing through its Esoterix Clinical Trials Services division. LabCorp clients include physicians, government agencies, managed care organizations, hospitals, clinical labs, and pharmaceutical companies. To learn more about our organization, visit our Web site at: www.labcorp.com. *Genzyme Genetics and its logo are trademarks of Genzyme Corporation and used by Esoterix Genetic Laboratories, LLC, a wholly-owned subsidiary of LabCorp, under license. Esoterix Genetic Laboratories and LabCorp are operated independently from Genzyme Corporation.

Contacts: IAVI
Lauren Wesolowski – lwesolowski@iavi.org, 212-328-7420
Sara Levy – slevy@iavi.org, 212-328-7415

The Scripps Research Institute
Mika Ono – mikaono@scripps.edu, 858-784-2052

Theraclone Sciences
Jacqui Miller – jmiller@macbiocom.com 781-235-3060
Doug MacDougall – dmacdougall@macbiocom.com

Laboratory Corporation of America
Steve Anderson – stephen.anderson@labcorp.com, 336-436-5274

ELSE PRESS RELEASES FROM THIS DATE:

Researchers push to import top anti-bullying program to US schools

2011-08-19

LAWRENCE, Kan. — An interdisciplinary team of researchers at the University of Kansas plan to bring a highly successful anti-bullying effort, the KiVa program, to American schools. Starting as early as the 2012-13 school year, a pilot program could kick off in selected classrooms in Lawrence, Kan. If shown to be successful there, soon afterward the model could expand nationally. KiVa, implemented in Finland in 2007, has impressed researchers with its proven reduction in bullying incidents. According to one recent study, KiVa "halved the risk of bullying others and of ...

Want to improve employee engagement? Make it part of the performance management process

2011-08-19

TORONTO, ON – The performance management process should evaluate and focus on employee engagement in addition to job performance, according to a paper published from the University of Toronto and University of Guelph. Engagement involves high levels of identification with one's work in terms of attention, absorption and feeling integrated in the performance of one's tasks and roles. The paper's authors – Professor Alan Saks from the University of Toronto and Professor Jamie Gruman of the University of Guelph – contend performance management should involve an evaluation ...

Study shows suburban schools have worked to 'hoard' advantages

2011-08-19

LAWRENCE, Kan. — As suburban school districts have gained advantages over their urban counterparts, they have tenaciously clung to them, often at the expense of urban districts, a new study by University of Kansas researchers shows. While urban schools' not keeping pace with suburban schools is an acknowledged problem, few have studied the causes of the discrepancies. John Rury and Argun Saatcioglu, professor and assistant professor of educational leadership and policy studies, recently published an article in the American Journal of Education showing how some suburban ...

Moon younger than previously thought

2011-08-19

Analysis of a piece of lunar rock brought back to Earth by the Apollo 16 mission in 1972 has shown that the Moon may be much younger than previously believed. This is concluded in new research conducted by an international team of scientists that includes James Connelly from the Centre for Star and Planet Formation, Natural History Museum of Denmark, University of Copenhagen. Their work has just been published in Nature. The prevailing theory of our Moon's origin is that it was created by a giant impact between a large planet-like object and the proto-Earth very early ...

American Chemical Society launches new edition of popular Bytesize Science videos

2011-08-19

WASHINGTON, Aug. 17, 2011 –– The American Chemical Society (ACS), the world's largest scientific society, today launched a new edition of its award-winning Bytesize Science video series, which has been fascinating thousands of viewers of all ages since its inception in 2007. Bytesize Science has received accolades from the National Science Teachers Association, the National Education Association, the National Science Foundation and the U. S. Environmental Protection Agency. The 2011 update refreshes Bytesize with a new logo and theme ("Uncover the Chemistry All Around ...

Study: College students not eating enough fruits and veggies

2011-08-19

CORVALLIS, Ore. – College students aren't eating enough fruits and vegetables – in fact, a new study shows students aren't even eating one serving per day, far from the recommended five daily servings. The study by Oregon State University researchers surveyed the eating habits of 582 college students, a majority of which were first-year students. The study, now online in the Journal of Nutrition Education and Behavior, compares male and female students, but found that both were not getting the proper amount of fruits and vegetables. Male students had about five servings ...

Milk better than water to rehydrate kids: McMaster study

2011-08-19

Hamilton, ON (August 17, 2011) – Active children need to be watered with milk. It's a more effective way of countering dehydration than a sports drink or water itself, say researchers at McMaster University. That's particularly important during hot summer weather, says Brian Timmons, research director of the Child Health and Exercise Medicine Program at McMaster and principal investigator of the study. "Children become dehydrated during exercise, and it's important they get enough fluids, particularly before going into a second round of a game. Milk is better than ...

Change the environment, not the child

2011-08-19

Hamilton, ON (August 16, 2011) -- A successful new rehabilitation approach to treating children with cerebral palsy puts its focus on where a child lives and plays, not just improving the child's balance, posture and movement skills. Called a "context-focused intervention", McMaster University and the University of Alberta researchers report in a new study this approach is just as beneficial as traditional child-focused therapy, offering parents an additional treatment option for their child. The McMaster study, in conjunction with researchers at the University of Alberta's ...

Arctic ice melt could pause in coming decades

2011-08-19

Despite the rapid retreat of Arctic sea ice in recent years, the ice may temporarily stabilize or somewhat expand at times over the next few decades, new research indicates. Results of a study by scientists at the National Center for Atmospheric Research (NCAR) appear this week in the journal Geophysical Research Letters (GRL), published by the American Geophysical Union. The National Science Foundation (NSF), NCAR's sponsor, funded the work. "As we learn more about climate variability, new and unexpected research results are coming to light," says Sarah Ruth, program ...

Better mattresses improve care, cut hospital costs: U of T study

2011-08-19

Toronto, August 17, 2011—Hospitals could reduce health care costs arising from pressure ulcers, commonly known as bedsores, by investing in pressure-reduction mattresses for elderly patients in emergency departments, according to new research from the University of Toronto. In emergency departments (EDs), elderly patients are at high risk for pressure ulcers in part because they spend hours lying on hard surfaces. The researchers found that while the average cost of upgrading from standard to pressure-redistribution mattresses would be 30 cents per patient, the corresponding ...

New West Health-Gallup survey finds incoming Trump administration faces high public skepticism over plans to lower healthcare costs

THE LANCET DIABETES & ENDOCRINOLOGY: Global Commission proposes major overhaul of obesity diagnosis, going beyond BMI to define when obesity is a disease.

Following a 2005 policy, episiotomy rates have reduced in France without an overall increase in anal sphincter injuries during labor, with more research needed to confirm the safest rate of episiotomi

AIDS researchers isolate new potent and broadly effective antibodies against HIV

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: